PETACH-TIKVA, Israel — May 5, 2026 — Leads & Copy — Discure Technologies, a clinical-stage medical device company, has appointed Ray Baker, M.D., to its Board of Directors. Baker brings over 30 years of experience in interventional pain, spine care, and medtech innovation.
Baker will also support the company as a fractional Chief Medical Officer. Discure is currently advancing the Discure System, a minimally invasive, implantable bioelectronic device designed to treat degenerative disc disease by addressing its underlying causes.
Yuval Mandelbaum, Chief Executive Officer of Discure Technologies, stated that Baker’s clinical credibility, operating experience, and perspective from working on both sides of the medtech landscape make him well-suited to support Discure.
Prior to this appointment, Baker served as Vice President and Chief Medical Officer of Neuromodulation at Boston Scientific. He also served as Chief Medical Officer of Relievant Medsystems, where he aided in clinical development, commercial introduction, and key reimbursement milestones before its acquisition by Boston Scientific. Baker is a past President of both the North American Spine Society and the International Pain and Spine Intervention Society and has advised CMS, the FDA, the CDC, and major private payors on spine and pain care.
Baker said that he has seen how limited the treatment options are for patients suffering from chronic low back pain associated with degenerative disc disease. He added that Discure’s early clinical outcomes gave him confidence that this technology could change how degenerative disc disease is managed.
Discure Technologies is developing a minimally invasive, implantable bioelectronic device designed to treat degenerative disc disease by controlling the reintroduction of fluid, oxygen, and nutrients into the degenerated disc. The Discure System aims to be the first disease-modifying solution for degenerative disc disease, with the potential to reduce the use of opioids and the need for invasive back surgery.
The Company received Breakthrough Device Designation from the FDA and was accepted into the agency’s Total Product Life Cycle Advisory Program (TAP), supporting a more efficient path toward market authorization and future patient access.
The Discure System is an investigational device and is not available commercially.
Source: Discure Technologies
